Metabolically healthy but obese individuals: relationship with hepatic enzymes

Metabolism: Clinical and Experimental

Volumn 59, Issue 1, 2010, Pages 20-24

  Messier, Virginie ^a,b   Karelis, Antony D ^c   Robillard, Marie Ève ^c   Bellefeuille, Philippe ^c   Brochu, Martin ^d,e   Lavoie, Jean Marc ^a   Rabasa Lhoret, Rémi ^a,b,f,g  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^c UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^d UNIVERSITÉ DE SHERBROOKE   (Canada)

^e UNIVERSITY INSTITUTE OF GERIATRICS OF SHERBROOKE   (Canada)

^f Montreal Diabetes Research Centre   (Canada)

^g CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER ENZYME; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY COMPOSITION; BODY MASS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME BLOOD LEVEL; FATTY LIVER; FEMALE; GLUCOSE TOLERANCE TEST; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; OBESITY; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRIORITY JOURNAL;

EID: 72049106119     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2009.06.020     Document Type: Article

References (33)

1. Lau D.C., Douketis J.D., Morrison K.M., et al. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children. CMAJ 176 (2007) S1-S13
2. Mulhall B.P., Ong J.P., and Younossi Z.M. Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol 17 (2002) 1136-1143
3. Brochu M., Tchernof A., Dionne I.J., et al. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women?. J Clin Endocrinol Metab 86 (2001) 1020-1025
4. Karelis A.D. Metabolically healthy but obese individuals. Lancet 372 (2008) 1281-1283
5. Karelis A.D., St-Pierre D.H., Conus F., et al. Metabolic and body composition factors in subgroups of obesity: what do we know?. J Clin Endocrinol Metab 89 (2004) 2569-2575
6. Sims E.A. Are there persons who are obese, but metabolically healthy?. Metabolism 50 (2001) 1499-1504
7. Aguilar-Salinas C.A., Garcia E.G., Robles L., et al. High adiponectin concentrations are associated with the metabolically healthy obese phenotype. J Clin Endocrinol Metab 93 (2008) 4075-4079
8. Karelis A.D., Faraj M., Bastard J.P., et al. The metabolically healthy but obese individual presents a favorable inflammation profile. J Clin Endocrinol Metab 90 (2005) 4145-4150
9. Lynch L.A., O'Connell J.M., Kwasnik A.K., et al. Are natural killer cells protecting the metabolically healthy obese patient?. Obesity (Silver Spring) 17 (2009) 601-605
10. Stefan N., Kantartzis K., Machann J., et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 168 (2008) 1609-1616
11. Meigs J.B., Wilson P.W., Fox C.S., et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 91 (2006) 2906-2912
12. Bonora E., Kiechl S., Willeit J., et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 47 (1998) 1643-1649
13. Ferrannini E., Natali A., Bell P., et al. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest 100 (1997) 1166-1173
14. Wildman R.P., Muntner P., Reynolds K., et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med 168 (2008) 1617-1624
15. Hanley A.J., Williams K., Festa A., et al. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes 54 (2005) 3140-3147
16. Hanley A.J., Williams K., Festa A., et al. Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 53 (2004) 2623-2632
17. Stefan N., Kantartzis K., and Haring H.U. Causes and metabolic consequences of Fatty liver. Endocr Rev 29 (2008) 939-960
18. Thamer C., Tschritter O., Haap M., et al. Elevated serum GGT concentrations predict reduced insulin sensitivity and increased intrahepatic lipids. Horm Metab Res 37 (2005) 246-251
19. Karelis A.D., Fontaine J., Messier V., et al. Psychosocial correlates of cardiorespiratory fitness and muscle strength in overweight and obese post-menopausal women: a MONET study. J Sports Sci 26 (2008) 935-940
20. Messier V., Karelis A.D., Lavoie M.E., et al. Metabolic profile and quality of life in class I sarcopenic overweight and obese postmenopausal women: a MONET study. Appl Physiol Nutr Metab 34 (2009) 18-24
21. Messier V., Malita F.M., Rabasa-Lhoret R., et al. Association of cardiorespiratory fitness with insulin sensitivity in overweight and obese postmenopausal women: a Montreal Ottawa New Emerging Team study. Metabolism 57 (2008) 1293-1298
22. Bedogni G., Bellentani S., Miglioli L., et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 6 (2006) 33
23. Matsuda M., and DeFronzo R.A. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22 (1999) 1462-1470
24. Andres R. Effect of obesity on total mortality. Int J Obes 4 (1980) 381-386
25. Sims E.A. Characterization of the syndromes of obesity. In: Brodoff B.N., and Bleicher S.J. (Eds). Diabetes mellitus and obesity (1982), Williams & Wilkins, Baltimore 219-226
26. Marchesini G., Avagnina S., Barantani E.G., et al. Aminotransferase and gamma-glutamyltranspeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome. J Endocrinol Invest 28 (2005) 333-339
27. Iacobellis G., Moschetta A., Buzzetti R., et al. Aminotransferase activity in morbid and uncomplicated obesity: predictive role of fasting insulin. Nutr Metab Cardiovasc Dis 17 (2007) 442-447
28. Lee D.H., Ha M.H., Kim J.H., et al. Gamma-glutamyltransferase and diabetes-a 4 year follow-up study. Diabetologia 46 (2003) 359-364
29. Lee D.H., Jacobs Jr. D.R., Gross M., et al. Gamma-glutamyltransferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem 49 (2003) 1358-1366
30. Ohlson L.O., Larsson B., Bjorntorp P., et al. Risk factors for type 2 (non-insulin-dependent) diabetes mellitus. Thirteen and one-half years of follow-up of the participants in a study of Swedish men born in 1913. Diabetologia 31 (1988) 798-805
31. Vozarova B., Stefan N., Lindsay R.S., et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 51 (2002) 1889-1895
32. Angulo P., and Lindor K.D. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol 17 Suppl (2002) S186-S190
33. Frayn K.N. Adipose tissue as a buffer for daily lipid flux. Diabetologia 45 (2002) 1201-1210